A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population
查看参考文献28篇
文摘
Objective: To evaluate the efficacy and safety of salvianolate in elderly patients with unstable angina pectoris (UAP). Methods: A prospective double-blind randomized placebo-controlled multicenter trial in elderly patients with UAP from 13 third-grade class-A hospitals in China was performed. A total of 318 patients were randomly allocated in a 1:1 ratio to an experimental group (160 patients) and a control group (158 patients). The experimental group was treated with salvianolate for 14 days on the basis of conventional medicine, and the control group was given a placebo for 14 days with the same criteria. Follow-up was lasted 28 days in both groups. The primary endpoint was biweekly frequency of angina pectoris attacks. The secondary endpoints included biweekly dosage of nitroglycerin, the Seattle Angina Questionnaire, angina pectoris severity and duration, myocardial injury markers, high-sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), as well as major adverse cardiovascular events (MACEs). Safety was assessed according to adverse events and serious adverse events. Results: Baseline characteristics were similar between treatment groups. Compared with those in the control group, the frequency of biweekly angina attacks (2.92 vs . 4.08, P =0.025), the biweekly dosage of nitroglycerin, as well as the severity and duration of angina attacks (P<0.01) were reduced by salvianolate. The Seattle Angina Questionnaire score was also significantly improved in the experimental group than in the control group (P<0.05). No significant differences were observed between the two groups with respect to the incidence of MACEs. Salvianolate was well tolerated. Conclusions: Salvianolate appear to have efficacy and well tolerated for elderly patients with UAP.
来源
Chinese Journal of Integrative Medicine
,2019,25(10):728-735 【核心库】
DOI
10.1007/s11655-019-2710-x
关键词
Salvianolate
;
unstable angina pectoris
;
elderly
;
efficacy
地址
1.
Department of Geriatric Cardiology, the General Hospital of the People's Liberation Army, Beijing, 100853
2.
Department of Geriatric Clinic, Inner Mongolia People's Hospital, Hohhot, 010017
3.
Department of Cardiology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210011
4.
Second Department of Cadre's Ward, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001
5.
Department of Cadre Health Care, Tianjin First Central Hospital, Tianjin, 300192
6.
Department of Cardiovascular Medicine, Chongqing General Hospital, Chongqing, 400013
7.
Department of Geriatrics, Shenyang Red Cross Hospital, Shenyang, 110063
8.
Department of Geriatric Cardiology, Guangzhou First People's Hospital, Guangzhou, 510180
9.
Department of Cardiology, Beijing Geriatric Hospital, Beijing, 100095
10.
the Second Department of Cardiology, the Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, 150009
11.
Department of Cardiology, Guizhou Province Hospital of Traditional Chinese Medicine, Guiyang, 550001
12.
Department of Cadre's Ward, the First Bethune Hospital of Jilin University, Changchun, 130021
13.
Department of Cadre Health Care, the First Affiliated Hospital of Wenzhou Medical University, Zhejiang, Wenzhou, 325000
14.
Medical Department, Shanghai Green Valley Pharmaceutical Co., Ltd., Shanghai, 201203
15.
China Health Promotion Foundation, Beijing, 100161
语种
英文
文献类型
研究性论文
ISSN
1672-0415
学科
内科学
基金
Supported by Science and Technology Commission of Shanghai Municipality
文献收藏号
CSCD:6573721
参考文献 共
28
共2页
1.
Braunwald E. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).
J Am Coll Cardiol,2002,40:1366-1374
CSCD被引
89
次
2.
Stone P H. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
J Am Coll Cardiol,2006,48:566-575
CSCD被引
7
次
3.
Holubkov R. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry.
Am Heart J,2002,144:826-833
CSCD被引
3
次
4.
Serruys P W. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.
New Engl J Med,2001,344:1117-1124
CSCD被引
19
次
5.
Antman E M. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
JAMA,2000,284:835-842
CSCD被引
85
次
6.
De Servi S. Non-ST-elevation acute coronary syndrome in the elderly: treatment strategies and 30-day outcome.
Am Heart J,2004,147:830-836
CSCD被引
3
次
7.
Jia J Y. Pharmacokinetics of depside salts from Salvia miltiorrhiza in healthy Chinese volunteers: A randomized, openlabel, single-dose study.
Current Therap Res Clin Exp,2010,71:260-271
CSCD被引
5
次
8.
Huang J. Protective effects of salvianolate on contrast-induced nephropathy after primary percutaneous coronary intervention: A prospective multicenter randomized controlled trial.
Cardiology,2017,138:169-178
CSCD被引
5
次
9.
Li X. Simultaneous determination of magnesium lithospermate B, rosmarinic acid, and lithospermic acid in beagle dog serum by liquid chromatography/tandem mass spectrometry.
Rapid commun Mass Spectro,2004,18:2878-2882
CSCD被引
9
次
10.
Zhang Y. A Chinese patent medicine Salvia miltiorrhiza depside salts for infusion combined with conventional treatment for patients with angina pectoris: A systematic review and meta-analysis of randomized controlled trials.
Phytomedicine,2017,25:100-117
CSCD被引
4
次
11.
Wu W Y. Pharmacological actions and therapeutic applications of Salvia miltiorrhiza depside salt and its active components.
Acta Pharmacol Sin,2012,33:1119-1130
CSCD被引
18
次
12.
Qi Y. Patient characteristics associated with treatment response in patients receiving salvianolate injection for stable angina.
J Evidence-Based Med,2018,11:83-88
CSCD被引
2
次
13.
Zhang D. Salvianolate injection in the treatment of unstable angina pectoris: A systematic review and meta-analysis.
Medicine,2016,95:e5692
CSCD被引
3
次
14.
Amsterdam E A. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol,2014,64:e139-e228
CSCD被引
102
次
15.
Anderson J L. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-STElevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.
J Am Coll Cardiol,2007,50:e1-e157
CSCD被引
89
次
16.
Chinese Society of Cardiology of Chinese Medical Association EBoCJoC. Guideline for diagnosis and treatment of patients with unstable angina and non-STsegment elevation myocardial infarction.
Chin J Cardiol (Chin),2007,35:295-304
CSCD被引
2
次
17.
Spertus J A. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease.
J Am Coll Cardiol,1995,25:333-341
CSCD被引
36
次
18.
Saunderson C E. Acute coronary syndrome management in older adults: guidelines, temporal changes and challenges.
Age Ageing,2014,43:450-455
CSCD被引
4
次
19.
Fei A H. Salvianolate inhibits reactive oxygen species production in H_2O_2-treated mouse cardiomyocytes in vitro via the TGFβ pathway.
Acta Pharmacol Sin,2013,34:496-500
CSCD被引
12
次
20.
Meng C. Protection of salvianolate against atherosclerosis via regulating the inflammation in rats.
J Huazhong Univ Sci Technol Med Sci (Chin),2014,34:646-651
CSCD被引
6
次
了解气象卫星更多信息，请访问